Dataset Information

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.

ABSTRACT: MALT1 cleavage activity is linked to the pathogenesis of activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL), a chemoresistant form of DLBCL. We developed a MALT1 activity assay and identified chemically diverse MALT1 inhibitors. A selected lead compound, MI-2, featured direct binding to MALT1 and suppression of its protease function. MI-2 concentrated within human ABC-DLBCL cells and irreversibly inhibited cleavage of MALT1 substrates. This was accompanied by NF-?B reporter activity suppression, c-REL nuclear localization inhibition, and NF-?B target gene downregulation. Most notably, MI-2 was nontoxic to mice, and displayed selective activity against ABC-DLBCL cell lines in vitro and xenotransplanted ABC-DLBCL tumors in vivo. The compound was also effective against primary human non-germinal center B cell-like DLBCLs ex vivo.

SUBMITTER: Fontan L

PROVIDER: S-EPMC3984478 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.

Fontan Lorena L Yang Chenghua C Kabaleeswaran Venkataraman V Volpon Laurent L Osborne Michael J MJ Beltran Elena E Garcia Monica M Cerchietti Leandro L Shaknovich Rita R Yang Shao Ning SN Fang Fang F Gascoyne Randy D RD Martinez-Climent Jose Angel JA Glickman J Fraser JF Borden Katherine K Wu Hao H Melnick Ari A

Cancer cell 20121201 6

MALT1 cleavage activity is linked to the pathogenesis of activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL), a chemoresistant form of DLBCL. We developed a MALT1 activity assay and identified chemically diverse MALT1 inhibitors. A selected lead compound, MI-2, featured direct binding to MALT1 and suppression of its protease function. MI-2 concentrated within human ABC-DLBCL cells and irreversibly inhibited cleavage of MALT1 substrates. This was accompanied by NF-κB reporter activity ...[more]

PMID: 23238016

Dataset Information

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.

Publications

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Similar Datasets

Blockade of oncogenic IkappaB kinase activity in ABC DLBCL by small molecule BET protein inhibitors
2014-08-01 | E-GEOD-58791 | biostudies-arrayexpress

A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.
| S-EPMC2858395 | biostudies-literature

Blockade of oncogenic IkappaB kinase activity in ABC DLBCL by small molecule BET protein inhibitors
2014-08-01 | GSE58791 | GEO

Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.
| S-EPMC6939458 | biostudies-literature

Enhancing functional platelet release in vivo from in vitro-grown megakaryocytes using small molecule inhibitors.
| S-EPMC5873227 | biostudies-literature

Glutaminolysis Mediated by MALT1 Protease Activity Facilitates PD-L1 Expression on ABC-DLBCL Cells and Contributes to Their Immune Evasion.
| S-EPMC6305595 | biostudies-literature

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
| S-EPMC3039817 | biostudies-literature

Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
| S-EPMC3601737 | biostudies-literature

Silencing heme oxygenase-1 increases the sensitivity of ABC-DLBCL cells to histone deacetylase inhibitor in vitro and in vivo.
| S-EPMC5667976 | biostudies-literature

Comprehensive in vitro characterization of PD-L1 small molecule inhibitors.
| S-EPMC6712002 | biostudies-literature